Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Department of Nephrology, Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Royal Brompton Hospital, London, United Kingdom
Gateway Medical Research Inc, St Charles, Missouri, United States
Gateway Medical Research Inc, St. Charles, Missouri, United States
Gateway Medical Research Inc., St.charles, Missouri, United States
Gateway Medical Research Inc., St.charles, Missouri, United States
Xiangshan People's Hospital, Xiangshan, Zhejiang, China
Renji Hospital, Shanghai, China
Shanghai 6th people's hospital, Shanghai, China
Jeroen Bosch Hospital, 's-Hertogenbosch, Noord Brabant, Netherlands
University Medical Center Nijmegen St Radboud, Nijmegen, Netherlands
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.